Research

Hormonal

Prolonged TNF-α antagonism via etanercept improves fasting glucose and increases the proportion of high molecular weight (HMW) adiponectin in obese subjects with metabolic syndrome.

For obese individuals with metabolic syndrome, blocking TNF-α using etanercept can lower fasting glucose and improve the beneficial ratio of high molecular weight adiponectin. This is not a standard weight-loss treatment due to infection risks, but it may be a beneficial side effect for patients already treating autoimmune diseases like rheumatoid arthritis.

GoodSupportsHIGH confidence
Prolonged therapy with etanercept improved fasting glucose, increased the ratio of high molecular weight to total adiponectin, and decreased sICAM-1 in obese subjects with abnormal glucose homeostasis and significant subclinical inflammation.
Takara L. Stanley et al. · The Journal of Clinical Endocrinology & Metabolism · 2010

Why this rating

Randomized, placebo-controlled, double-blind design with a relatively long duration (6 months) and specific population (obese, metabolic syndrome).

Source

TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome

Takara L. Stanley et al. · The Journal of Clinical Endocrinology & Metabolism · 2010

DOI 10.1210/jc.2010-1170

rct · n=40Cited 319×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →